Department of Surgery, Mount Sinai Medical Center, Miami Beach, Florida.
Division of Cardiac Surgery, CardioVascular Center, Tufts Medical Center, Boston, Massachusetts.
Ann Thorac Surg. 2023 Jun;115(6):1503-1509. doi: 10.1016/j.athoracsur.2022.09.027. Epub 2022 Sep 28.
Although the use of extended criteria donors (ECDs) is traditionally avoided because of poorer outcomes, management of heart transplant (HTx) recipients has evolved over the past decades. We sought to examine the temporal trends in outcomes of ECDs in HTx.
We queried the United Network for Organ Sharing database for adult HTx recipients who fit the EXPAND Trial criteria for ECDs: ischemic time ≥ 4 hours, ejection fraction < 50%, age > 55 years, and history of coronary artery disease. Transplant years were stratified into the following 4 periods: (1) 2000 to 2004, (2) 2005 to 2009, (3) 2010 to 2014, and (4) 2014 to 2018. The 2-sample t test, Kaplan-Meier survival analysis, log-rank test, analysis of variance, multivariable Cox proportional hazards, and multinomial logistic regression were used to compare data between periods.
Through periods 1 to 4, 39,028 patients were stratified as follows: 9217 (2942 ECDs, 31.9%), 9224 (2730 ECDs, 29.6%), 10,309 (2762 ECDs, 26.8%), and 10,278 (2190 ECDs, 21.3%). Transplants using ECDs in periods 1 and 2 had increased 1-year mortality compared with periods 3 and 4 (16.9% and 15.6% vs 11.9% and 10.9% respectively, P < .001). Later periods also demonstrated improved Karnofsky scores (P < .001).
Although use of ECDs decreased across the periods, we noted significant improvement in 1-year survival rates and postoperative functional status.
尽管传统上避免使用扩展标准供者(ECD),因为其预后较差,但过去几十年来,心脏移植(HTx)受者的管理已经发生了变化。我们试图研究 ECD 在 HTx 中的结果的时间趋势。
我们在 United Network for Organ Sharing 数据库中查询了符合 EXPAND 试验 ECD 标准的成年 HTx 受者:缺血时间≥4 小时、射血分数<50%、年龄>55 岁和冠心病史。移植年份分为以下 4 个时期:(1)2000 年至 2004 年,(2)2005 年至 2009 年,(3)2010 年至 2014 年,和(4)2014 年至 2018 年。使用两样本 t 检验、Kaplan-Meier 生存分析、对数秩检验、方差分析、多变量 Cox 比例风险和多项逻辑回归来比较各期之间的数据。
通过第 1 至第 4 期,将 39028 名患者分层如下:9217 名(2942 名 ECD,31.9%)、9224 名(2730 名 ECD,29.6%)、10309 名(2762 名 ECD,26.8%)和 10278 名(2190 名 ECD,21.3%)。与第 3 和第 4 期相比,第 1 和第 2 期使用 ECD 的移植术的 1 年死亡率更高(分别为 16.9%和 15.6%,以及 11.9%和 10.9%,P<.001)。后期也显示出卡诺夫斯基评分的改善(P<.001)。
尽管 ECD 的使用在各期均有所下降,但我们注意到 1 年生存率和术后功能状态的显著改善。